CHASM-CS Registry

Registry for the Cardiac Sarcoidosis Multi-Center Cohort

Objective

1. To follow clinical outcomes in patients with clinically manifest CS.

2. To follow clinical outcomes in patients with clinically silent CS in comparison to controls i.e. patients with extra-cardiac sarcoidosis with no evidence of CS. 

  1. Inclusion

    Clinically Manifest CS:

    • < 60 years old

    • Unexplained, new onset significant conduction disease (2nd or 3rd degree AV block)

    • Idiopathic sustained monomorphic VT (in a structurally normal heart

    Clinically Silent CS:

    • Diagnosed (by biopsy) pulmonary/systemic sarcoidosis and abnormal:

    • ECG: LBBB, RBBB, path. Q waves in 2+ leads

    • Holter: VT (sustained or nonsustained)

    • Echo: RWMA/aneurysm, EF < 50% 

  2. Exclusion

    None

Enrolling

Additional Info

Ethics ID: REB15-0329

ClinicalTrials.gov ID: NCT01477359

 

Sponsor: Ottawa Heart Institute Research Corporation

 

PI: Dr. Russell Quinn

Phone: 403 210 6152

 

Admin: Jennifer McKeage

Phone: 403 210-6047

E-mail: jmckeage@ucalgary.ca